Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 1/20 | 0.59 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.59 |
| ▸ | CDC25A | P30304 | 1/20 | 0.58 |
| ▸ | CDC25B | P30305 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15256362 | 0.88 | CDC25A (0.53) | CDC25ACDC25BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL10272535 | 0.87 | PIK3C2B (0.61) | PIK3C2BPIK3C2GPIK3CDPIK3CAPIK3CB | |
| SCHEMBL188662 | 0.86 | PIK3CG (0.71) | CDC25ACDC25BPIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL14861065 | 0.85 | PIK3CG (0.70) | CDC25ACDC25BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL190125 | 0.84 | MAPT (0.62) | PIK3C2BPIK3C2GPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14873744 | 0.81 | PIK3CG (0.80) | PIK3C2BPIK3C2GCDC25ACDC25BPIK3CD | |
| SCHEMBL189686 | 0.79 | PIK3CG (0.61) | PIK3C2BPIK3C2GPIK3CDPIK3CAPIK3CB | |
| SCHEMBL10044532 | 0.78 | RXFP1 (0.72) | CDC25ACDC25BMAPTKDM4EPOLB | |
| SCHEMBL14301188 | 0.78 | PIK3CD (0.61) | PIK3C2BPIK3C2GPIK3CDPIK3CAPIK3CB | |
| SCHEMBL189404 | 0.78 | PIK3CG (0.71) | PIK3C2BPIK3C2GPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3C2B 12/4885PIK3C2G 74/4885CDC25A 193/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3C2B 12/4885PIK3C2G 74/4885CDC25A 193/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3C2B 18/4885PIK3C2G 74/4885CDC25A 153/4885 |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | ERBB2, EGFR, ERBB3 | PIK3C2B 367/4885PIK3C2G 798/4885CDC25A 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.